Comparison of injectable collagen medical device vs. hyaluronate for knee osteoarthritis .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2016;4(21):10 BMC Musculoskelet Disord. 2016 Feb 22;17(1):9464 patients with mild-moderate knee osteoarthritis were randomized to intra-articular injection of either sodium hyaluronate (SUPARTZ; Seikagaku) or a new collagen medical device (MD-Knee; Guna S.p.a). The purpose of this study was to compare the two groups based on function and knee pain over 6 month follow-up. Results demonstrated no significant differences in either knee function or pain scores at 3 or 6 months after enrollment. Additionally, there were no significant differences between groups in general health-related quality of life, or the rate of patients who required additional acetaminophen.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sí = 1
Incierto = 0,5
No relevante = 0
No = 0
La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.
2/4
Randomization
3/4
Outcome Measurements
4/4
Inclusion / Exclusion
3/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.
¿Por qué se necesitaba ahora este estudio?
The topic of conservative management of knee osteoarthritis has been debated significantly in recent years. One of the most prominent treatment methods as of late is the intra-articular injection of sodium hyaluronate (HA). Another more recent intra-articular treatment that has been developed is the use of a collagen medical device (MD-Knee; Guna S.p.a), though its efficacy has yet to be tested in a randomized controlled trial.
¿Cuál era la pregunta principal de la investigación?
What are the effects of a collagen medical device (MD-Knee; Guna S.p.a) compared to intra-articular injection of sodium hyaluronate (SUPARTZ; Seikagaku) in patients with mild-moderate knee osteoarthritis, assessed over 6 month follow-up after enrollment?
- At 3 months (primary endpoint), there was no significant difference in mean Lequesne Knee Index between the MD-Knee group (8.59 +/- 4.71) and the SUPARTZ group (9.79 +/- 4.43) (p=0.330). There was also no significant difference between groups in improvement in mean LKI from baseline to 3 months (p=0.368).
- At 6 months, there was also no significant difference in mean LKI between the MD-Knee group (9.12 +/- 3.89) and the SUPARTZ group (9.28 +/- 4.28) (p=0.621).
- There were no significant differences between the MD-Knee group and SUPARTZ group at 6 months for either VAS pain (5.42 +/- 2.69 vs. 4.43 +/- 2.63, respectively; p=0.275) or SF-36 scores (88.37 +/- 28.83 vs. 92.07 +/- 23.37, respectively; p=0.462).
- Additional analgesic consumption (acetaminophen) occurred in 12/31 (38.7%) in the MD-Knee group and 13/29 (44.8%) in the SUPARTZ group.
- One patient in the MD-Knee discontinued treatment due to a moderate post-injection reaction.
¿Qué es lo que más debo recordar?
In the treatment of mild-moderate knee osteoarthritis, there was no significant difference in knee function or pain over 6 month follow-up between intra-articular administration of a collagen medical device (MD-Knee; Guna S.p.a) or sodium hyaluronate (SUPARTZ; Seikagaku). Additional analgesics were still needed by approximately 40% of patients.
¿Cómo afectará esto al cuidado de mis pacientes?
The results of this study suggest that the newly developed collagen medical device may offer short-term results similar to sodium hyaluronate in knee osteoarthritis treatment. However, as there is still controversy regarding the clinical efficacy of hyaluronate products in knee osteoarthritis treatment, and there was no placebo group included in the current study, additional placebo-controlled trials are necessary to more adequately assess the clinical efficacy of the collagen medical device within this patient population.
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
